Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists

Michael J. Rybak, Jennifer Le, Thomas P. Lodise, Donald P. Levine, John S. Bradley, Catherine Liu, Bruce A. Mueller, Manjunath P. Pai, Annie Wong-Beringer, John C. Rotschafer, Keith A. Rodvold, Holly D. Maples, Benjamin M. Lomaestro

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Background: Recent vancomycin PK/PD and toxicodynamic studies enable a reassessment of the current dosing and monitoring guideline in an attempt to further optimize the efficacy and safety of vancomycin therapy. The area-under-the-curve to minimum inhibitory concentration (AUC/MIC) has been identified as the most appropriate pharmacokinetic/pharmacodynamic (PK/PD) target for vancomycin. The 2009 vancomycin consenus guidelines recommended specific trough concentrations as a surrogate marker for AUC/MIC. However, more recent toxicodynamic studies have reported an increase in nephrotoxicity associated with trough monitoring. Methods and Results: This is the executive summary of the new vancomycin consensus guidelines for dosing and monitoring vancomycin therapy and was developed by the American Society of Health-Systems Pharmacists, Infectious Diseases Society of America, Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists vancomycin consensus guidelines committee. Conclusions: The recommendations provided in this document are intended to assist the clinician in optimizing vancomycin for the treatment of invasive MRSA infections in adult and pediatric patients. An AUC/MIC by broth microdilution (BMD) ratio of 400 to 600 (assuming MICBMD of 1 mg/L) should be advocated as the target to achieve clinical efficacy while improving patient safety for patients with serious MRSA infections. In such cases, AUC-guided dosing and monitoring is the most accurate and optimal way to manage vancomycin therapy.

Original languageEnglish (US)
Pages (from-to)363-367
Number of pages5
JournalPharmacotherapy
Volume40
Issue number4
DOIs
StatePublished - Apr 1 2020

Bibliographical note

Publisher Copyright:
© 2020 Pharmacotherapy Publications, Inc.

Keywords

  • nephrotoxicity
  • pharmacokinetics and pharmacodynamics
  • target attainment
  • vancomycin
  • vancomycin consensus guidelines

Fingerprint

Dive into the research topics of 'Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists'. Together they form a unique fingerprint.

Cite this